The conversation around GLP-1 drugs has turned a corner. What began as coverage of weight loss and diabetes management now centers on a different question: whether these compounds can slow the aging process and extend the years people stay healthy. At the center of that shift is Nir Barzilai, M.D., director of the Institute for Geroscience at Albert Einstein College of Medicine, whose decades of research on centenarians established the scientific foundation for treating aging as a targetable condition.
In September, Barzilai was the named expert in National Geographic's Why GLP-1s Could Be an Anti-Aging Breakthrough and recorded a long-form episode with Levels, Can We Actually Measure How Fast You're Aging? His centenarian-offspring research also anchored SciTechDaily's Children of Centenarians Have a 42% Lower Risk of Death, Study Finds. The common thread: Barzilai's work has given clinical grounding to the claim that aging itself has biological drivers that can be measured, targeted, and slowed.
From centenarians to geroprotection
Barzilai's studies of families of more than 800 centenarians revealed that exceptionally long-lived people do not just live longer. They delay the onset of age-related diseases by 20 to 30 years and show a pronounced compression of morbidity, spending relatively little time ill at the end of life. His cohorts helped identify genetic variants that appear to slow the aging process, and several have been translated into FDA-approved drugs.
That research shaped the design of the Targeting Aging with Metformin trial, known as TAME, which Barzilai conceived. TAME is the first trial designed to test whether a drug can delay multiple age-related diseases at once by targeting the biology of aging rather than fighting diabetes, cardiovascular disease, cancer, dementia, and frailty one disease at a time. The GLP-1 conversation is now following the same logic.
Why GLP-1s are part of the geroscience conversation
GLP-1 drugs were developed to treat type 2 diabetes and obesity. But the emerging evidence suggests they may also reduce cardiovascular events, inflammation, and other markers associated with biological aging. Barzilai's framework helps explain why: if aging has measurable biological drivers, and if a compound affects those drivers in a way that delays disease onset across multiple systems, then it is targeting aging, not just one condition.
The National Geographic piece positioned Barzilai as the clinical researcher translating that claim into testable hypotheses. The Levels episode walked through the biomarkers his team is using to measure biological age, including work through FAST, a collaboration between the American Federation for Aging Research and ARPA-H. The SciTechDaily coverage reinforced the centenarian-offspring findings that anchor his approach: children of centenarians have a 42% lower risk of death, and understanding why is the key to extending health span in the general population.
What this means for strategy
For executive audiences, Barzilai translates geroscience into questions about talent planning, benefits design, prevention, and the economics of productivity. If aging can be measured and targeted, then organizations can begin to think about health not as a fixed cost that rises with an aging workforce, but as a variable that responds to intervention. That changes the conversation around benefits, chronic disease management, and workforce planning.
Barzilai is careful about what the science does not yet show. His message is not about chasing immortality. It is about extending the years people stay healthy, capable, and productive, and understanding which interventions have evidence behind them and which are speculative. For leadership teams debating how longevity reshapes their industry, that distinction matters.
Nir Barzilai is exclusively represented by Stellant Group for keynotes, board sessions, and confidential advisory work with leadership teams thinking through how geroscience, longevity, and the targeting of biological aging reshape workforce strategy, benefits design, and the economics of health and productivity.
